AN2 Therapeutics, Inc. 8-K

What Happened
AN2 Therapeutics, Inc. announced on March 8, 2026 that it entered into a Securities Purchase Agreement with certain investors for a private placement. The deal covers the sale of 8,245,611 shares of common stock and pre‑funded warrants to purchase up to 5,789,493 additional shares. The price is $2.85 per share and $2.84999 per pre‑funded warrant, and the company expects aggregate gross proceeds of approximately $40 million (before placement agent fees and expenses). The closing is expected to occur on March 10, 2026. The company filed a press release on March 9, 2026 announcing the transaction.

Key Details

• Shares: 8,245,611 shares of common stock; Pre‑Funded Warrants to buy up to 5,789,493 shares.
• Prices: $2.85 per share; $2.84999 per pre‑funded warrant.
• Warrant terms: exercise price $0.00001 per share; no expiration until fully exercised; includes a beneficial‑ownership blocker (default 9.99%, can be adjusted up to 19.99% after notice and 61 days).
• Registration & timing: Company will file a resale registration statement within 30 days after closing and will use reasonable best efforts to have it declared effective; company agreed not to issue other shares (with certain exceptions) until the Registration Statement is effective or 60 days after closing.

Why It Matters
This transaction is intended to raise near‑term financing of roughly $40 million to support the company’s operations or development plans. The issuance will increase the number of shares outstanding and could dilute existing shareholders when shares are issued or pre‑funded warrants are exercised. The pre‑funded warrants limit immediate dilution because they require exercise to convert to common stock, but they have a very low exercise price and will expand the float once exercised. The registration commitment means the investors’ shares and warrants should be resaleable in the public market once the registration is effective, which can affect trading liquidity and supply.